301 related articles for article (PubMed ID: 26991464)
1. The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples.
Ebisch RM; de Kuyper-de Ridder GM; Bosgraaf RP; Massuger LF; IntHout J; Verhoef VM; Heideman DA; Snijders PJ; Meijer CJ; van Kemenade FJ; Bulten J; Siebers AG; Bekkers RL; Melchers WJ
Int J Cancer; 2016 Aug; 139(3):691-9. PubMed ID: 26991464
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
Song F; Du H; Wang C; Huang X; Wu R;
PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
[TBL] [Abstract][Full Text] [Related]
3. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
4. Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
Cuzick J; Adcock R; Carozzi F; Gillio-Tos A; De Marco L; Del Mistro A; Frayle H; Girlando S; Sani C; Confortini M; Zorzi M; Giorgi-Rossi P; Rizzolo R; Ronco G;
Int J Cancer; 2020 Oct; 147(7):1864-1873. PubMed ID: 32170961
[TBL] [Abstract][Full Text] [Related]
5. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
[TBL] [Abstract][Full Text] [Related]
6. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy.
Dijkstra MG; van Niekerk D; Rijkaart DC; van Kemenade FJ; Heideman DA; Snijders PJ; Meijer CJ; Berkhof J
Cancer Epidemiol Biomarkers Prev; 2014 Jan; 23(1):55-63. PubMed ID: 23733907
[TBL] [Abstract][Full Text] [Related]
7. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA.
Stoler MH; Baker E; Boyle S; Aslam S; Ridder R; Huh WK; Wright TC
Int J Cancer; 2020 May; 146(9):2599-2607. PubMed ID: 31490545
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: A pooled analysis of individual patient data from nine population-based cervical cancer screening studies from China.
Dun C; Yuan M; Zhao X; Hu S; Arbyn M; Zhao F
Cancer Med; 2024 Jun; 13(11):e7316. PubMed ID: 38828559
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
11. Comparison of different strategies for the triage to colposcopy of women tested high-risk HPV positive on self-collected cervicovaginal samples.
Chatzistamatiou K; Tsertanidou A; Moysiadis T; Mouchtaropoulou E; Pasentsis K; Skenderi A; Stamatopoulos K; Agorastos T
Gynecol Oncol; 2021 Sep; 162(3):560-568. PubMed ID: 34210517
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
13. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening.
Rijkaart DC; Berkhof J; van Kemenade FJ; Coupe VM; Hesselink AT; Rozendaal L; Heideman DA; Verheijen RH; Bulk S; Verweij WM; Snijders PJ; Meijer CJ
Int J Cancer; 2012 Feb; 130(3):602-10. PubMed ID: 21400507
[TBL] [Abstract][Full Text] [Related]
15. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.
Luttmer R; Berkhof J; Dijkstra MG; van Kemenade FJ; Snijders PJ; Heideman DA; Meijer CJ
J Clin Virol; 2015 Jun; 67():59-66. PubMed ID: 25959161
[TBL] [Abstract][Full Text] [Related]
16. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of p16
Song F; Belinson JL; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
Gynecol Oncol; 2021 Aug; 162(2):322-330. PubMed ID: 34059349
[TBL] [Abstract][Full Text] [Related]
18. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R
Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038
[TBL] [Abstract][Full Text] [Related]
19. Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.
Leeman A; Del Pino M; Marimon L; Torné A; Ordi J; Ter Harmsel B; Meijer CJLM; Jenkins D; Van Kemenade FJ; Quint WGV
Int J Cancer; 2019 Jan; 144(1):160-168. PubMed ID: 30098013
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of two strategies to follow-up ASC-US and LSIL screening results in The Netherlands using repeat cytology with or without additional hrHPV testing: a retrospective cohort study.
Siebers AG; Arbyn M; Melchers WJ; van Kemenade FJ; Vedder JE; van der Linden H; van Ballegooijen M; Bekkers RL; Bulten J
Cancer Causes Control; 2014 Sep; 25(9):1141-9. PubMed ID: 24935226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]